Self-assembled nanoparticle containing gB protein of EB virus and preparation method and use thereof

Patent metadata

Field	Value
Publication number	US-12098167-B2
Application number	US-202017762308-A
Country	US
Kind code	B2
Filing date	Dec 15, 2020
Priority date	Dec 7, 2020
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

The present invention is related to a self-assembled nanoparticle containing a gB protein of an EB virus and a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide; the first polypeptide comprises the gB protein and a first vector subunit, the second polypeptide comprises a second vector subunit; the first vector subunit is I53-50A1, and the second vector subunit is I53-50B.4PT1. In the self-assembled nanoparticle, the gB protein of the EB virus is displayed on the surface of the nanoparticle for the first time. The particle size of the self-assembled nanoparticle is larger than that of the antigen gB, and the chemical stability of the self-assembled nanoparticle is higher than that of the antigen gB, and the binding capacity with the neutralizing antibody of the self-assembled nanoparticle are higher than that of the antigen gB.

First claim

The invention claimed is:

1. A self-assembled nanoparticle, comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a gB protein and a first vector subunit, the second polypeptide comprises a second vector subunit; the first vector subunit is I53-50A1, and the second vector subunit is I53-50B.4PT1; and the gB protein is linked to the first vector subunit through a linker peptide;
wherein, the amino acid sequence of the I53-50A1 is SEQ ID NO: 1; the amino acid sequence of the I53-50B.4PT1 is SEQ ID NO: 2;
the amino acid sequence of the gB protein is SEQ ID NO: 3.

2. The self-assembled nanoparticle according to claim 1 , wherein, the first polypeptide further comprises a stable protein; the stable protein is located between the first vector subunit and the linker peptide.

3. The self-assembled nanoparticle according to claim 2 , wherein the first polypeptide is a part of a first polypeptide trimer, and the second polypeptide is a part of a second polypeptide pentamer.

4. The self-assembled nanoparticle according to claim 3 , wherein there are 18 to 22 trimers in the nanoparticle and wherein there are 10 to 14 pentamers in the nanoparticle.

5. A preparation method of the self-assembled nanoparticle according to claim 1 , comprising incubating the first polypeptide and the second polypeptide to obtain the self-assembled nanoparticle.

6. A vaccine, comprising the self-assembled nanoparticle according to claim 1 .

7. The self-assembled nanoparticle according to claim 1 , wherein the linker peptide is a polypeptide containing 5 amino acids to 20 amino acids.

8. The self-assembled nanoparticle according to claim 1 , wherein the linker peptide is a polypeptide with the amino acid sequence of any one of SEQ ID NO: 4 to SEQ ID NO: 9.

9. The self-assembled nanoparticle according to claim 2 , wherein the stable protein is T4 fibritin (SEQ ID NO: 10) or GCN4 peptide fragment (SEQ ID NO: 11).

10. The preparation method of the self-assembled nanoparticle according to claim 5 , wherein the molar mass ratio of the first polypeptide to the second polypeptide is 1:(3).

11. The vaccine according to claim 6 , further comprising an adjuvant.

12. A drug for preventing Epstein-Barr virus infection, comprising the self-assembled nanoparticle according to claim 1 .

13. A method for preventing Epstein-Barr virus infection, comprising administering to a subject in need thereof an effective amount of the self-assembled nanoparticle according to claim 1 .

14. A drug for treating diseases caused by Epstein-Barr virus infection, comprising the self-assembled nanoparticle according to claim 1 .

15. A method for treating diseases caused by Epstein-Barr virus infection, comprising administering to a subject in need thereof an effective amount of the self-assembled nanoparticle according to claim 1 .

Assignees

• Univ Sun Yat Sen
• Sun Yat Sen Univ Cancer Center Sysucc

Inventors

• Zeng Musheng
• Sun Cong
• Zeng Yixin
• Feng Guokai
• Kang Yinfeng
• Chen Xinchun
• Zhang Xiao
• Zhu Qianying
• Li Jiangping
• Kong Xiangwei

Classifications

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title

• A61K39/245

  Herpetoviridae, e.g. herpes simplex virus · CPC title

• A61K9/51

  Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)} · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61K2039/5258

  Virus-like particles · CPC title